DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer

Scientists reported that DAB2IP was mutated or selectively silenced in the vast majority of KRAS and BRAF mutant colorectal cancers. DAB2IP loss promoted tumor development by activating wild-type H- and N-RAS proteins.